Background {#Sec1}
==========

Cancer is the second leading cause of death of non-communicable diseases worldwide \[[@CR1]\]. Its prevalence increased by 25.4% between 2007 and 2017, and population ageing contributed about 22% to this increase \[[@CR1]\]. Prevalence and incidence of cancer in people aged 70 years and older were estimated to be about 27.1 and 9.6 million cases in 2017 \[[@CR2]\].

Due to the effects of both, the disease and its usually intensive treatment, patients with cancer have an increased risk of malnutrition. Various cancer-related mechanisms, such as systemic inflammation \[[@CR3]\] and hypoxic stress \[[@CR4]\] affect the patients' nutritional status. Patients might already present lower dietary intake before anticancer treatment \[[@CR5]\] and in addition, side effects of anticancer therapy, e. g. loss of appetite, dry mouth or nausea that are associated with a lower energy intake \[[@CR6]\]. The prevalence of malnutrition in patients with cancer is described by 26--42% \[[@CR7]--[@CR9]\], and varies between different operationalisations \[[@CR10]--[@CR12]\]. To better reflect the health status of an older patient before treatment decisions are made by oncologists, a (comprehensive) geriatric assessment is recommended \[[@CR13]--[@CR15]\], consisting of several domains such as functional status, cognition, comorbidity or polypharmacy and it is also recommended that it should contain a domain regarding the patients' nutritional status assessed by validated tools such as the Mini Nutritional Assessment (MNA)® \[[@CR15]\]. A recent study by Kenis et al. could show that components of comprehensive geriatric assessment are prognostic factors (especially functional status and nutritional status) for overall survival in patients with cancer which additionally highlights the need for nutritional assessment \[[@CR16]\]. It was also shown, that (severe) malnutrition is independently associated with mortality risk and decreased tolerance of chemotherapy \[[@CR17]\]. Therefore, early detection and treatment of malnutrition is recommended for the prevention of cancer-related adverse outcomes \[[@CR18]--[@CR20]\].

However, no gold standard for screening and assessment of malnutrition in cancer patients exists. Among 37 malnutrition screening and assessment methods utilized for patients with cancer in clinical practice, in a recent systematic review, the MNA scored highest for the calculated content validity \[[@CR21]\]. This tool is validated to identify persons aged 65 years or older who are at risk of malnutrition or malnourished \[[@CR22]--[@CR25]\].

The MNA is widely used in patients with cancer of all ages \[[@CR26]\], even though it is neither developed specifically for this disease nor for persons younger than 65 years. Both versions, the short-form (MNA-SF) and long-form (MNA-LF), are recommended for screening of nutritional status of older patients in all clinical settings \[[@CR27]\]. For patients with cancer, the use of MNA-SF is recommended by medical oncology societies for older patients with cancer \[[@CR28], [@CR29]\] as well as by practicing oncologists \[[@CR30]\]. A summary of results about the association between MNA and relevant patient outcomes is currently lacking. Thus, our aim was to systematically summarize the existing evidence regarding nutritional status according to the MNA as potential prognostic factor for health and treatment outcomes in cancer patients.

Methods {#Sec2}
=======

This systematic review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR31]\]. A protocol describing the methodological procedure was prepared before the start and is available upon request.

Systematic literature search {#Sec3}
----------------------------

A systematic literature search using database specific search strategies was conducted in MEDLINE and EMBASE (via Ovid), the Cochrane Library and CINAHL (via EBSCOhost) in June 2017 for studies published in any language from 1994 (first published version of MNA) onwards. The search was updated twice, in September 2018 and March 2020. Search strategies have been developed by 1 reviewer (GT) and discussed by the working group members (GT, TS, EK and DV) and a librarian. The search strategies included a combination of keywords and MeSH−/ Emtree-terms (e.g. nutritional status, MNA, cancer) (Additional file, table [1](#MOESM1){ref-type="media"}). Additionally, reference lists of included studies were searched.

Study selection {#Sec4}
---------------

Original articles of longitudinal studies reporting a potential association between nutritional status assessed by MNA (any form) at baseline and any health or treatment outcome (e.g. mortality, survival, complications) at a later time point in patients of any age with any type of cancer and anticancer therapy were included. Studies with a cross-sectional design and those not using MNA-assessed nutritional status for predicting health and treatment outcomes were excluded as well as other publication types (e.g. conference abstracts or editorials). Currently, 2 forms of the MNA are available, which were both included. The short-form (SF) consisting of 6 items (A-F), first developed in 2001 \[[@CR24]\] and revised in 2009 (range 0--14 points; 0--7 points: malnourished; 8--11 points: at risk of malnutrition and 12--14 points: normal nutritional status) \[[@CR23]\], and the long-form (LF) or "full MNA" consisting of additional 12 items (G-R) \[[@CR22], [@CR25]\] (range 0--30 points; 0--17 points: malnourished; 17--23.5 points: at risk of malnutrition and 24--30 points: normal nutritional status).

Titles/abstracts and full texts were screened by 2 reviewers (GT, TS) independently. Conflicts were solved by discussion or by a third reviewer (EK).

Data extraction {#Sec5}
---------------

Two reviewers (GT, TS) independently extracted the following data using a piloted extraction form:

a\) [Study characteristics]{.ul}: first author, year of publication, country, sample size.

b\) [Participant characteristics]{.ul}: age, sex, type of cancer, cancer stage, anticancer therapy (e.g. chemotherapy).

c\) [Malnutrition screening tool and result]{.ul}: MNA form (MNA-SF or -LF), MNA result as reported by the authors (prevalence of malnutrition, risk of malnutrition and well-nourished patients and/or mean/median score.

d\) [Outcome characteristics]{.ul}: follow-up time, prevalence or incidence of any reported outcome at/during follow-up; results on prognostic effects (e.g. odds ratios (OR), hazard ratios (HR) for respective outcome (e.g. mortality)) from multivariable analyses.

Assessment of risk of bias {#Sec6}
--------------------------

Two reviewers (GT, EK) independently assessed the risk of bias (RoB) of each included study using a specified version of the QUIPS-tool \[[@CR32]\] (Additional file, table [2](#MOESM1){ref-type="media"}). We predefined a set of core confounders (cancer stage, type of cancer, type of therapy, sex, age, performance status, co-morbidity) and dropped the first item 'definition of the prognostic factor' of the '*prognostic factor measurement*' domain since we were interested in nutritional status according to MNA as the only prognostic factor. The item '*valid and reliable measurement of prognostic factor*' was rated as having a low risk of bias when the study reported all 3 MNA-categories or the MNA-score.

The domains study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding and statistical analysis and reporting were rated with either low, moderate or high RoB and are separately presented for each study. Conflicts were solved by discussion or a third reviewer (DV).

Data synthesis {#Sec7}
--------------

Reported outcomes were classified in 7 categories: (a) mortality/ poor overall survival, (b) progression-free survival and time to progression, (c) treatment maintenance or duration, (d) adverse treatment outcomes (toxicity, complications), (e) functional status / decline and (f) quality of life and (g) other outcomes.

Due to a high heterogeneity of patient populations and reported outcomes meta-analyses were not possible.

Results {#Sec8}
=======

Study selection {#Sec9}
---------------

After removing duplicates, we screened 6080 titles/abstracts and 859 full-texts for potential eligibility. Finally, 56 studies \[[@CR16], [@CR33]--[@CR87]\] were included, all of them published in English language. Main reasons for exclusion were wrong publication type (e.g. conference abstract), no use of MNA, or no longitudinal study design/predictive purpose (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1PRISMA Flow chart

Study and patient characteristics {#Sec10}
---------------------------------

Detailed study and patient characteristics are presented in Table [1](#Tab1){ref-type="table"}. Table 1Study and patient characteristics of included studiesAuthor/ YearCountry***N***^**a**^Age (years)^**b**^Female (%)Type of cancerCancer stage (early/ mixed/ advanced)Anticancer therapyMNA-formMNA-result^**c**^OutcomeMN (%)AR (%)WN (%)Aaldriks 2011NL20277 ± 455VariousMixedChemoSF/LF^d^2.529.764.9Mortality^e^Treatment maintenanceAaldriks 2013aNL14375 (70--92)41ColorectalMixedChemoSF/LF^d^28.072.0MortalityTreatment maintenanceAaldriks 2013bNL5576 ± 596BreastAdvancedChemoSF/LF^d^41.854.5MortalityTreatment maintenanceAaldriks 2015NL4478 (70--86)57VariousMixedChemoSF/LF^d^34.165.9MortalityTreatment maintenanceAaldriks 2016NL49475 (70--92)51VariousMixedChemoSF/LF^d^35.264.0MortalityTreatment maintenanceAllaire 2017Canada14469 ± 1022BladderMixedSurgerySF9.043.048.0ComplicationsAparicio 2018France10281 (75--89)45ColorectalAdvancedChemoSF66.733.3MortalityPFSAraujo 2017Brazil5253 (24--85)^f^71VariousMixedChemoLF23.5 ± 4.2^g^FatigueBaier 2016Germany19575 (70--88)31Variousn.r.Surgeryn.r.n.r.56.7^h^n.r.Functional statusBoulahssass 2018France105082 (70--100)60VariousMixedVariousLF21.047.728.5MortalityD'Almeida 2020Brazil306173 ± 744VariousMixedVariousSF33.439.327.3Length of hospital stayDecoster 2016Belgium19377 (70--89)38ColorectalMixedVariousLF56.044.0Functional declineToxicityDecoster 2018Belgium25277 (69--91)39ColorectalAdvancedVariousLF54.245.8PFSTreatment durationDecoster 2019Belgium297279 ± 657VariousMixedVariousSF79.121.9Quality of LifeDubruille 2015Belgium9074 (65--89)43HematologicalMixedChemoLF44.056.0MortalityExtermann 2012USn.a.^i^76 (70--92)50VariousMixedChemoLF25 (8--30)^g^ToxicityFrasca 2018France126478 ± 570VariousMixedVariousLF41.558.5MortalityGhosn 2017France10076 (4)^j^47Variousn.r.VariousSFn.r.n.r.n.r.MortalityGiannotti 2019Italy9980 ± 638ColorectalMixedSurgeryLF23.12 ± 3.31^g^MortalityGiannousi 2012Greece12266 (37--81)16LungAdvancedSystemicLF9.060.730.3MortalityGioulbasanis 2011aGreece17365 ± 1117LungAdvancedVariousLF26.046.227.8MortalityTTPGioulbasanis 2011bGreece11566 (32--86)12LungAdvancedChemoLF25.251.323.5MortalityGioulbasanis 2012Greece11468 ± 511LungAdvancedSystemicLF29.841.229.0MortalityTTPGioulbasanis 2015France, Greece59469 ± 1027VariousAdvancedSystemicLF12.849.537.7MortalityGoineau 2018France10078 (75--89)0ProstateAdvancedRadioLF2.098.0Quality of LifeGu 2015China30056 ± 1233Renal cellAdvancedn.r.SF4.017.378.7MortalityToxicityHonecker 2018Germany160780Prostaten.r.VariousSF61.638.4Treatment maintenanceHoppe 2013France29977 (70--93)41VariousAdvancedChemoLF63.236.8Functional declineKaibori 2016Japan7178 ± 527Hepatocellularn.r.SurgerySF43.756.3ComplicationsKenig 2015Poland7573 ± 644VariousVariousSurgeryLF48.052.0ComplicationsKenis 2017Belgium43975 (70--95)58VariousMixedVariousSF21.446.931.7MortalityFunctional declineKenis 2018BelgiumCohort A: 763Cohort A: 76 (70--95)Cohort A: 68VariousMixedVariousSFCohort A: 62.3Cohort A: 37.7MortalityCohort B: 402Cohort B: 77 (70--95)Cohort B: 67Cohort B: 56.5Cohort B: 43.5Kim 2014Korea98n.a.^k^31VariousMixedChemoLF20.447.030.6Treatment maintenanceKristjansson 2010Norway1828057ColorectalMixedSurgeryLF9.545.645.0MortalityComplicationsLiuu 2020France109282 ± 547VariousMixedVariousLF145036MortalityUnplanned admissionLycke 2019Belgium94480 (70--99)48VariousMixedVariousSF7327MortalityMartucci 2016Brazil13673 ± 748VariousMixedn.r.SF29.441.229.4MortalityMazzuca 2019ItalyProLYOtin: 22ProLYOtin: 68 (34--83)ProLYOtin: 32ColorectalMixedChemoLFProLYOtin: 18ProLYOtin: 50ProLYOtin: 32ToxicityPlacebo: 25Placebo: 67 (49--85)Placebo: 44Placebo: 16Placebo: 36Placebo: 48Michaan 2020Korea12076 ± 5100GynaecologicMixedVariousLF20.4 ± 4.6^g^MortalityMolga 2020Australia9877 (66--95)37HematologicalMixedVariousLF2773MortalityTreatment maintenanceNaito 2016Japan9377 (65--90)^f^54Non-Hodgkin LymphomaMixedVariousLF40.959.1MortalityOsborne 2017UK17874 (70--84)0ProstateMixedVariousSF0.06.782.6ToxicityPark 2015Korea7074 (65--92)46LymphomasMixedChemoSF35.737.127.1MortalityTreatment maintenanceQuinten 2019Belgium74181 (70--89)43VariousMixedSurgerySF74.425.6Quality of Life68377 (70--94)47Chemo81.418.6Retornaz 2020France9779 (75--83)^l^51ColorectalAdvancedChemoSF61.938.1MortalityToxicitySamuelsson 2019Sweden4981 (77--85)^l^53ColorectalMixedSurgerySF38.861.2ComplicationsLength of hospital stayScholtz 2018Germany51771 (68--74)^l^32VariousMixedSurgeryLF2.323.873.9ComplicationsSchütte 2015Germany5166 ± 1014HepatocellularMixedn.r.LF0.017.362.7MortalityShin 2012Korea6471 (65--80)25VariousMixedChemoLF21.959.418.7ToxicityShiroyama 2017Japan3076 (70--83)13LungAdvancedChemoSF0.0^m^66.733.3ToxicitySoubeyran 2012France34877 (70--99)41VariousMixedChemoLF64.935.1MortalityStauder 2020Austria14778 (67--98)46HematologicalMixedVariousLF154342Mortalityvan Deudekom 2019NL10279 (72--85)^l^30Head & NeckMixedVariousSF39.261.8Mortalityvan der Vlies 2019NL9977 (69--85)^l^37VariousAdvancedChemoLF85.015.0Treatment maintenanceToxicityVande Walle 2014Belgium93776 (70--95)64VariousMixedn.r.SF18.745.036.6FallsVlachostergios 2013Greece10367 (32--84)10LungAdvancedSystemicLF30.139.830.1MortalityPFSLegend: ^a^Number of included patients; ^b^mean ± standard deviation (SD) or median (range); ^c^percentages may not add up to 100 due to rounding or missing values; ^d^stepwise process -- patients were classified as WN when SF \> 12 or LF 24--30; ^e^studies that were categorized to 'mortality' reported results on mortality or (poor) overall survival; ^f^mean (range); ^g^MNA-LF-score: X ± Y: mean ± SD or X (Y-Z) median (range: 0--30); ^h^"Based on literature and the distribution of the mean values in the current study population" \[[@CR23]\]; ^i^total: 518; ^j^median (SD); ^k^87.8 ≥ 70 years; ^l^interquartile-range (IQR); ^m^MN patients were excluded from study participation*MNA* Mini Nutritional Assessment; *SF* short-form; *LF* long-form; *MN* malnourished; *AR* at risk for malnutrition; *WN* well-nourished; *n.a* not applicable; *n.r.* not reported; *PFS* progression-free survival; *TTP* time to progression; *NL* The Netherlands; *UK* United Kingdom; *US* United States of America

Most of the studies \[[@CR16], [@CR33]--[@CR37], [@CR39], [@CR41], [@CR42], [@CR44]--[@CR47], [@CR49]--[@CR57], [@CR59], [@CR60], [@CR62], [@CR63], [@CR65]--[@CR67], [@CR69], [@CR73], [@CR75]--[@CR79], [@CR82]--[@CR87]\] were conducted in Northern, Western or Southern Europe, 5 studies \[[@CR38], [@CR40], [@CR43], [@CR48], [@CR68]\] in North or South America and 8 \[[@CR58], [@CR61], [@CR64], [@CR70], [@CR72], [@CR74], [@CR80], [@CR81]\] in Eastern Asia.

The number of included patients ranged from 30 to 2972, mean/median age from 53 to 82 years. In 8 studies \[[@CR40], [@CR52]--[@CR54], [@CR56], [@CR58], [@CR69], [@CR87]\] also patients \< 65 years were included. In 3 of these studies \[[@CR40], [@CR53], [@CR58]\] mean age was 65 years or lower.

The percentage of female patients in studies including both sexes (*N* = 52) ranged from 9.7--96.0%. Three studies only included patients with prostate cancer \[[@CR57], [@CR59], [@CR73]\] and one study only patients with gynecologic cancer \[[@CR70]\].

Almost half of the studies \[[@CR16], [@CR34]--[@CR36], [@CR40]--[@CR43], [@CR45], [@CR48]--[@CR50], [@CR55], [@CR60], [@CR62], [@CR63], [@CR66]--[@CR68], [@CR75], [@CR78], [@CR80], [@CR82], [@CR84], [@CR86]\] reported on patients with various types of cancer. Thirty studies \[[@CR33], [@CR37]--[@CR39], [@CR44], [@CR46], [@CR47], [@CR51]--[@CR54], [@CR56]--[@CR59], [@CR61], [@CR65], [@CR69]--[@CR74], [@CR76], [@CR77], [@CR79], [@CR81], [@CR83], [@CR85], [@CR87]\] focused on a specific type, with lung \[[@CR52]--[@CR54], [@CR56], [@CR81], [@CR87]\] and colorectal cancer \[[@CR37], [@CR39], [@CR44], [@CR46], [@CR51], [@CR65], [@CR69], [@CR76], [@CR77]\] as the most common types. Fifteen studies \[[@CR33], [@CR39], [@CR44], [@CR52]--[@CR58], [@CR60], [@CR76], [@CR81], [@CR84], [@CR87]\] included only patients with advanced cancer, while 2 studies \[[@CR57], [@CR73]\] excluded patients with metastatic cancer. For studies reporting various cancer stages (*N* = 26), the percentage of patients with stage III and stage IV (metastatic) ranged from 15 to 56% and from 4 to 86%, respectively.

MNA {#Sec11}
---

In 30 studies \[[@CR40], [@CR42], [@CR44], [@CR46]--[@CR49], [@CR51]--[@CR57], [@CR60], [@CR62], [@CR64]--[@CR66], [@CR69]--[@CR72], [@CR78]--[@CR80], [@CR82]--[@CR84], [@CR87]\] the MNA-LF, in 20 studies \[[@CR16], [@CR38], [@CR39], [@CR43], [@CR45], [@CR50], [@CR58], [@CR59], [@CR61], [@CR63], [@CR67], [@CR68], [@CR73]--[@CR77], [@CR81], [@CR85], [@CR86]\] the MNA-SF, and in 5 studies \[[@CR33]--[@CR37]\] a stepwise approach that considered both forms was used. One study \[[@CR41]\] did not report the MNA-version.

All MNA-categories (malnourished, at risk of malnutrition and well-nourished) were reported in 25 studies \[[@CR35], [@CR38], [@CR42], [@CR43], [@CR52]--[@CR56], [@CR58], [@CR63]--[@CR66], [@CR68], [@CR69], [@CR73], [@CR74], [@CR78]--[@CR81], [@CR83], [@CR86], [@CR87]\] with prevalence of malnutrition ranging from 0 to 35.7% and of risk of malnutrition from 6.7--66.7%. Twenty-three studies \[[@CR16], [@CR33], [@CR34], [@CR36], [@CR37], [@CR39], [@CR44]--[@CR47], [@CR49], [@CR59]--[@CR62], [@CR67], [@CR71], [@CR75]--[@CR77], [@CR82], [@CR84], [@CR85]\] merged patients with malnutrition and at risk of malnutrition, and reported 27.0--85.0% being at least at risk, while 2 other studies \[[@CR57], [@CR72]\] merged patients at risk of malnutrition and well-nourished patients. Four studies reported a mean or median baseline MNA-score \[[@CR40], [@CR48], [@CR51], [@CR70]\], and 2 studies did not report concrete results \[[@CR41], [@CR50]\].

Reported outcomes {#Sec12}
-----------------

Thirty-three studies investigated the association between MNA and mortality / (poor) overall survival, 3 reported progression-free survival, 2 time to progression, 11 treatment maintenance, 15 adverse treatment outcomes, 4 functional status or decline, 3 (health-related) quality of life (Table [2](#Tab2){ref-type="table"} and Additional file table [3](#MOESM1){ref-type="media"}a-f). Other outcomes were less often reported: length of hospital stay in 2 studies and falls, fatigue and unplanned admission in 1 study, each and are reported in the results section. Table 2Univariate and multivariable associations of MNA and the most frequent investigated health and treatment outcomes in patients with cancerStudyN^**a**^Type of cancerMean/ median follow-up^**b**^ (months)Association with MNA andMortality/ poor survivalProgression-free survival/ Time to progressionTreatment maintenance/\
-durationComplicationsFunctional status/ -declineQuality of LifeTreatment toxicityPostoperative complicationsADLIADLAaldriks 2011202Various9**+ ++**Aaldriks 2013a143Colorectal15any CT: **+ +**adjuvant CT: **-- --**palliative: **+ ++ +**Aaldriks 2013b55Breast16**+ +--**Aaldriks 201544Various46**--+ +**Aaldriks 2016494Various17**+ ++ +**Allaire 2017144Bladder0.2 or2**-- ---- --**Aparicio 2018102Colorectal20.4**----**Baier 2016195Various6**--**Boulahssass 20181050Various3.3**+ +**Decoster 2016193Colorectal2--3Grade 4 HT: **-- --**Grade 4 NHT: **-- ------**Decoster 2018252Colorectaln.r.**+ +--**Decoster 20192972Various3**+ +**Dubruille 201590Hematological12**--**Extermann 2012n.a.^c^Various1HT: **-- --**NHT: **+ +**Frasca 20181264Various123660**+ ++ +-- --**Ghosn 2017100Various47.3**--**Giannotti 201999Colorectal12**--**Giannousi 2012122Lung70**+ +**Gioulbasanis 2011a173Lung24**+ ++ +**Gioulbasanis 2011b115Lung38.2**+ +**Gioulbasanis 2012114Lung24.3**+ ++ +**Gioulbasanis 2015594Various27**+ +**Goineau 2018100Prostate2**--**Gu 2015300Renal cell30.8**+ +-- --**^e^Honecker 2018160Prostaten.r.**----**Hoppe 2013299Variousn.r.**+**Kaibori 201671Hepatocellularn.r.**--**Kenig 201575Various1**--**Kenis 2017439Variousn.r.**+ ++ +--**Kenis 2018Cohort A: 763VariousCohort A: 61.4**+ +**Cohort B: 402Cohort B: 45.7**+ +**Kim 201498Various15.1**+ +**Kristjansson 2010182Colorectal20**+ +--**^f^Liuu 20201092Various15.3**+**Lycke 2019944Various12**+ +**Martucci 2016136Various12**+ +**Mazzuca 2019ProLYOtin^d^: 22Colorectal3**+**Placebo: 25Michaan 2020120Gynaecologic\> 4**+ +**Molga 202098Hematologicaln.r.**----**Naito 201693Non-Hodgkin Lymphoman.r.**--**Osborne 2017178Prostate3**--**Park 201570Lymphomas21.5**+ ++ +**Quinten 2019Surgery: 741Various3**+ +**Chemo: 683**--**Retornaz 202097Colorectal16.7**----**Samuelsson 201949Colorectal≤0.1**--**Scholtz 2018517Various1**+**Schütte 201551Hepatocellular7.3**+**Shin 201264Various2.1**--**Shiroyama 201730Lungn.r.**+**Soubeyran 2012348Various6**+ +**Stauder 2020147Hematological24**+**van Deudekom 2019102Head & Neck12**+ +**van der Vlies 201999Variousn.r.**----**Vlachostergios 2013103Lung38.2**+ +--Proportion of studies with significant results in multivariable analyses22/27(=81%)3/5(=40%)5/8(=63%)1/5(=20%)0/2(=0%)1/3(=33%)0/2(=0%)2/2(=100%)**Legend: ^a^: Number of included patients; ^b^: median (range), mean ± SD or pre-defined follow-up time; ^c^: total: 518; ^d^: Highly purified, whey protein group; ^e^: at 30 days; ^f^: 1 month+ +: MNA significantly associated with outcome in multivariable analyses-- --: MNA not significantly associated with outcome in multivariable analyses+: MNA significantly associated with outcome in univariate regression analyses or by other statistical tests (e.g. chi-square), and no multivariable analyses reported or MNA not included in multivariable model--: MNA not significantly (*p* \< 0.05) associated with outcome in univariate analyses or by other statistical tests (e.g. chi-square)*HT* hematologic toxicity; *NHT* non-hematologic toxicity; *(I)ADL* (instrumental) activities of daily living; *n.r*. not reported

Mortality / (poor) overall survival {#Sec13}
-----------------------------------

In 10 studies a specific follow-time point was reported (100 and 500 days, 6, 12, 24, 36 and 60 months), in 20 studies follow-up times varied with median follow-up times between 9 and 70 months. Mortality rates varied between 16% in 6 months and 94% in 38 months (29 studies). The mean/ median time for overall survival ranges from 5 to 38 months (9 studies) (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}a).

All studies analyzing the malnourished category separately (*N* = 7) report significant results with 3 to 8 times higher chance for mortality for malnourished compared to well-nourished patients \[[@CR42], [@CR53], [@CR55], [@CR56], [@CR58], [@CR68], [@CR87]\]. In all of these studies, the chance for mortality was lower in patients at risk of malnutrition than in malnourished patients, but still significant in 4 studies \[[@CR42], [@CR53], [@CR55], [@CR56]\].

In 1 study reporting 12-, 36- and 60 months-mortality in patients with (risk of) malnutrition compared with well-nourished patients, significance was lost at 60 months \[[@CR49]\]. In 12 of 18 studies with a combined malnutrition/ at risk of malnutrition group, the chance for mortality was also significantly increased \[[@CR33], [@CR35]--[@CR37], [@CR54], [@CR63], [@CR65], [@CR82]\] compared to well-nourished patients in multivariable analyses. In a subgroup analysis in 1 of these studies, the relation remained only significant in patients receiving palliative chemotherapy but not in patients with adjuvant chemotherapy \[[@CR37]\]. In 1 \[[@CR74]\] of 2 studies \[[@CR72], [@CR74]\] the chance for mortality was significantly higher for patients with malnutrition when compared to those being at risk of malnutrition or well-nourished. One study \[[@CR52]\] showed a significant association of MNA with mortality but did not report whether the continuous or categorical MNA-result was used for analysis, while another study showed also a significant association but used the MNA-score \[[@CR67]\]. Six other studies only reported results from univariate analyses \[[@CR51], [@CR59], [@CR72], [@CR76], [@CR79], [@CR83]\].

Progression-free survival and time to progression {#Sec14}
-------------------------------------------------

Of 3 studies \[[@CR39], [@CR44], [@CR87]\] examining progression-free survival in patients with either colorectal or lung cancer, only 1 \[[@CR44]\] found the MNA to be predictive (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}b).

Two studies investigated the prognostic ability of MNA for time to progression of metastatic lung cancer \[[@CR53], [@CR56]\]. Both reported a higher chance for a longer time to progression for well-nourished patients when compared to patients at risk of malnutrition and malnourished patients in multivariable analyses.

Treatment maintenance {#Sec15}
---------------------

Treatment maintenance was examined in 3 ways: not completing scheduled chemotherapy cycles, treatment discontinuation and treatment duration.

Not completing the scheduled cycles of chemotherapy was investigated in 7 studies \[[@CR33]--[@CR37], [@CR74], [@CR84]\] and those presenting adjusted analyses (*n* = 3) showed a significant higher chance for patients with (risk of) malnutrition compared to well-nourished patients \[[@CR34], [@CR36], [@CR37]\] or malnourished patients compared to those who were well-nourished or at risk of malnutrition \[[@CR74]\]. Two studies did not report an adjusted analysis \[[@CR35], [@CR84]\] and in 1 study a significant association could not be obtained in multivariable analysis \[[@CR33]\] (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}c).

One \[[@CR64]\] of 3 studies \[[@CR59], [@CR64], [@CR71]\] focusing on treatment discontinuation reported a significantly higher chance for patients with malnutrition compared to those who were well-nourished or at risk of malnutrition.

One further study \[[@CR44]\] focused on treatment duration and failed to show an association with MNA-result at baseline.

Adverse treatment outcomes {#Sec16}
--------------------------

Nine studies investigated the association between baseline MNA and treatment toxicity \[[@CR46], [@CR48], [@CR58], [@CR69], [@CR73], [@CR76], [@CR80], [@CR81], [@CR84]\] (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}d). In only 1 of these studies \[[@CR48]\], a significant higher risk for non-hematologic toxicity was shown for patients with (risk of) malnutrition compared to well-nourished patients, while for other toxicity outcomes (hematologic, acute radiotherapy or significant toxicity) MNA-result was not predictive \[[@CR46], [@CR73], [@CR80]\] or not investigated in adjusted analyses \[[@CR69], [@CR76], [@CR81], [@CR84]\].

In all 6 studies reporting various kinds of postoperative complications, MNA did not maintain significant results or was not investigated in multivariable analyses \[[@CR38], [@CR61], [@CR62], [@CR65], [@CR77], [@CR78]\].

Functional status/ decline {#Sec17}
--------------------------

One study identified functional limitations defined as Barthel-ADL \< 95 after 6 months in 10% of patients with various types of cancer and reported no significant association of this outcome with the baseline MNA-result in the unadjusted analysis (Chi^2^-test) \[[@CR41]\] (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}e).

Functional decline in activities of daily living and instrumental activities of daily living was examined in 3 studies \[[@CR46], [@CR60], [@CR63]\] with different tools and was not significantly associated with the MNA-result in all but 1 study, where the odds for ADL-decline was two-fold in patients with (risk of malnutrition) compared to well-nourished patients \[[@CR63]\]. Another study in about 300 patients with various types of cancer did not conduct multivariable analyses \[[@CR60]\].

(health-related) quality of life {#Sec18}
--------------------------------

Three studies reported (Health-related) quality of life \[[@CR57]\] (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}f). Until a follow-up of 2 months, quality of life declined in 30% of patients with localized advanced prostate cancer and a low prevalence of malnutrition at baseline (2%), but the study did not report adjusted analyses related to its association with baseline MNA \[[@CR57]\]. In two studies \[[@CR45], [@CR75]\] reporting on patients with various types of cancer and a follow-up of 3 months, patients with (risk of) malnutrition had a significantly lower chance for a decline in health-related quality of life compared to well-nourished patients. In one of these studies, this effect was not maintained in in the multivariable analysis in patients receiving chemotherapy \[[@CR75]\].

Other outcomes {#Sec19}
--------------

Two studies reported results on length of hospital stay investigated in univariate analyses \[[@CR43], [@CR77]\] . In 1 study \[[@CR77]\], length of hospital stay was longer in patients with malnutrition while in the other study \[[@CR43]\], nutritional status according to MNA did not show an association.

One study showed that MNA-score was predictive for fatigue evaluated by the Chalder Fatigue Scale (mean value at follow-up 26.8 ± 4.8; correlation coefficient *r* = − 0.52, *p* = 0.01) but not by the Brief Fatigue Inventory (mean value at follow-up 22.4 ± 23.7; correlation coefficient and *p*-value not reported) in chemotherapy-treated patients with various types of cancer and a mean age of 53 years \[[@CR40]\].

In 1 study reporting a fall incidence of about 18% during 2--3 months, nutritional status was not a prognostic factor for patients with various kinds and stages of cancer (not significant in multivariable analysis) \[[@CR86]\].

Another study including patients with various types of cancer reported a significant univariate association between MNA and unplanned (hospital) admissions but did not consider MNA for further multivariable analyses \[[@CR66]\].

Risk of Bias {#Sec20}
------------

The RoB of all studies was moderate to high (Additional file 2, table [3](#MOESM1){ref-type="media"}). Main sources of potential bias were residual confounding due to missing prespecified potential confounding variables (e.g. age, sex, performance status) in multivariable models.

Discussion {#Sec21}
==========

In this systematic review, we investigated the prognostic significance of baseline nutritional status according to MNA regarding health and treatment outcomes in patients with cancer. In 56 studies included in our review, we found that, based on a moderate to high risk of bias, poor nutritional status is associated with a significantly higher risk for mortality / poor overall survival (22/27 studies), longer progression-free survival / time to progression (3/5 studies), worse treatment maintenance (5/8 studies) and (health-related) quality of life (2/2 studies) in multivariable analyses. Adverse treatment outcomes (1/7 studies) and functional decline (1/3 studies) were not significantly predicted by MNA in adjusted analyses while other outcomes were not investigated in multivariable analyses.

The **MNA** was originally developed to identify patients 65 years or older at risk of malnutrition irrespective of a specific disease \[[@CR23], [@CR25]\].

The **prevalence of malnutrition**, risk of malnutrition or their combination was 0--41%, 7--67%, and 28--67%, respectively -- however not reported in all studies (Additional file [1](#MOESM1){ref-type="media"}, Table [1](#Tab1){ref-type="table"}). We could not identify a trend for a higher or lower prevalence of malnutrition in studies including patients with a specific kind or stage of cancer as documented in a large cohort study from Italy including 1952 patients with various types and stages of cancer. There, a prevalence for malnutrition of 8.7% and risk of malnutrition of 42.4% was reported for all patients, but when stratified for cancer stage, both MNA-categories, malnutrition and risk of malnutrition were significantly higher in stage IV compared to stage I-III cancer \[[@CR88]\]. A meta-analysis of studies including hospitalized patients older than 60 years with any disease, reported a prevalence for malnutrition of 22.0% (95%-CI: 18.9--25.2) and risk of malnutrition 45.6% (95%-CI: 42.7--48.6) \[[@CR89]\]. Recently, a consensus for the diagnosis of malnutrition, the Global Leadership Initiative on Malnutrition (GLIM)-criteria, was published \[[@CR90]\] and a few studies regarding nutritional status in patients with cancer are available. Prevalence rates for malnutrition according to GLIM were reported between 25.8 and 80% - depending on the criteria which were used for the diagnosis according to GLIM \[[@CR91]--[@CR93]\].

We could show that the **chance for mortality** was higher in patients being malnourished and at risk of malnutrition compared to well-nourished patients in the majority of studies (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}a). This is in line with 3 recently published systematic reviews also addressing the relation between malnutrition and mortality in patients with cancer \[[@CR94]--[@CR96]\]. While their approaches and search strategies differed with respect to inclusion of other screening tools and prespecified outcomes, there is an overlap of included MNA-studies. However, we could identify additional studies, so that our systematic review adds further evidence for the relationship between nutritional status assessed by MNA and mortality. Other systematic reviews with focus on a specific type of cancer (pancreatic, gastrointestinal) \[[@CR97]--[@CR99]\] or cancer stage (advanced) \[[@CR100]\] reported that mortality risk / overall survival is predicted by nutritional status according to low body mass index, the Prognostic Nutritional Index, Controlling Nutritional status and phase angle \[[@CR97]--[@CR100]\]. For the Patient-Generated Subjective Global Assessment, which is also often used and recommended for nutritional screening in patients with cancer, several primary studies investigated the association with mortality/ overall survival and showed conflicting results with a majority of studies predicting a higher risk \[[@CR101]--[@CR104]\]. Two studies investigated the association between malnutrition according to the GLIM-criteria and mortality/ poor survival and both could show significant results \[[@CR91], [@CR92]\]. Future studies should investigate the application and prognostic abilities of these criteria. Additionally, an analysis including several cohorts of patients with cancer could show that the risk for mortality was higher in patients with lower body mass index and higher weight loss \[[@CR105]\]. In one study (which was excluded), machine learning algorithms were used to predict early death in older patients with cancer \[[@CR106]\]. Questionnaire items from the comprehensive geriatric assessment were selected by artificial intelligence and the MNA-SF remained in the predictive model. Such studies might be used in future to gain further knowledge of the prognostic factors in patients with cancer. Regarding other diseases, a meta-analysis found nutritional status according to MNA being predictive for mort ality in patients with heart failure \[[@CR107]\].

Besides mortality risk, **time to progression and progression-free survival** are often used endpoints in clinical trials to evaluate the efficacy of anti-cancer treatment, since the treatment intention is either curation or a longer survival with a higher quality of life \[[@CR108]\], but were only rarely investigated in relation to MNA. We found evidence that a poor MNA-result is predictive for a shorter time to progression / progression-free survival (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}b). These endpoints are mostly not clearly defined, but it is generally agreed among experts that time to progression reflects the time to cancer progression whereas progression-free survival also includes death from any cause \[[@CR109], [@CR110]\]. However, it is discussed whether these endpoints are meaningful outcomes in cancer research, since a recent systematic review, including about 14,000 adult patients until 93 years with various kinds of cancer, showed that a prolonged progression-free survival is not associated with a higher health-related quality of life \[[@CR111]\]. The association between a poorer nutritional status and a higher risk for a shorter progression-free survival was also shown in a recent meta-analysis investigating the prognostic ability of the Prognostic Nutritional Index in patients with hepatocellular carcinoma \[[@CR112]\]. For other tools, primary studies found a shorter progression-free survival significantly predicted by nutritional status assessed by the Geriatric Nutritional Risk Index or the Controlling Nutritional Status Score in different types of cancer \[[@CR113], [@CR114]\], but systematic reviews are lacking.

When patients with cancer had poor MNA at baseline, **treatment maintenance** was poorer but treatment duration (1 study) was not shorter (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}c). Main reasons for poorer maintenance were toxicity, cancer progression and insufficient therapeutic effect \[[@CR33]--[@CR36]\].

In included studies investigating **toxicity** as a separate outcome, a significant association with MNA-result at baseline was not found. Only non-hematologic toxicity was predicted by a poorer nutritional status according to MNA in 1 study \[[@CR48]\] (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}d). Also, **complications after surgery** were not predicted by MNA (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}d). This is in line with results of other systematic reviews including patients with various kinds of cancer that showed a lower chance of treatment-related adverse events by geriatric assessment components only according to functional status, cognition and depression but not by nutritional status according to various definitions \[[@CR95], [@CR115], [@CR116]\]. In contrast, in adult patients undergoing joint arthroplasty or hip fracture surgery, malnutrition defined by serologic markers (e.g. albumin, lymphocyte count, transferrin) was predictive for a higher risk of postoperative outcomes, such as wound complications \[[@CR117], [@CR118]\]. One study in older hip-fracture patients showed that patients with (risk of) malnutrition patients -- according to MNA-SF -- were at higher risk for postoperative delirium compared to well-nourished patients \[[@CR119]\]. In another study, a significant association between malnutrition and chemotherapy related toxicity could be showed for the Patient-Generated Subjective Global Assessment but not for the Nutritional Risk Index \[[@CR103]\]. To clarify these conflicting results, further studies are required in patients with cancer.

Only 1 of 3 studies predicted functional decline in basic activities of daily living by poor MNA-result and all 3 studies failed to predict a decline in instrumental activities of daily living (Additional file, table [3](#MOESM1){ref-type="media"}e). In older hospitalized patients with various diseases, nutritional status according to Short Nutritional Assessment Questionnaire was also not related to functional decline \[[@CR120]\] but a moderate association was found for MNA in older people from different settings (i.e. community-dwelling, acute, subacute or residential care) \[[@CR121]\]. A systematic review of studies including older hospitalized patients with various diseases revealed that baseline functional and cognitive status as well as social support were more important to predict functional outcomes than nutritional status \[[@CR122]\]. These results demonstrate the need for further studies regarding the association between MNA and functional decline in patients with cancer.

For **(health-related) quality of life**, 1 study that was identified by our systematic literature search was only small, including patients with prostate cancer. Only 2% were malnourished and unfortunately no adjusted analysis was reported \[[@CR57]\]. Two other studies that we also included could show a lower chance for a decline in health-related quality of life for patients with (risk of) malnutrition \[[@CR45], [@CR75]\] (Table [2](#Tab2){ref-type="table"}, Additional file table [3](#MOESM1){ref-type="media"}f). This finding might be explained by the already poor quality of life at baseline or, in other words that after anticancer therapy the chance for an improvement in quality of life was higher for patients with (risk of) malnutrition compared to well-nourished patients with already better quality of life.

Regarding length of hospital stay (2 studies), fatigue, falls and unplanned admissions (1 study each), only a very small number of studies investigated the association with baseline MNA with no multivariable analyses, and more studies are needed also in this regard to draw any conclusion.

Several limitations of the included studies need to be considered. First, risk of bias was judged as moderate to high in all included studies, which is in contrast to other systematic reviews reporting a low to moderate risk of bias \[[@CR94], [@CR95]\]. Our rating is mainly explained by insufficient consideration of potential confounders -- which have been predefined by 2 reviewers (cancer stage, type of cancer, sex, age, performance status, co-morbidity) -- in multivariable analyses of primary studies to minimize the risk of residual confounding which is generally one of the most relevant limitations of observational studies \[[@CR123]--[@CR125]\]. Second, in several studies \[[@CR33], [@CR34], [@CR37], [@CR42], [@CR53], [@CR56], [@CR58], [@CR61], [@CR64], [@CR68], [@CR74], [@CR80], [@CR82], [@CR87]\], effect estimates had relatively wide confidence intervals and this imprecision should be considered when interpreting these results. Reasons for imprecisions might be an insufficient number of participants or malnourished patients. Third, follow-up times differed widely between the studies and only a few defined or reported a specific time point for outcome assessment. Mostly only vague information about follow-up times, such as a mean overall survival, was provided. Thus, conclusions for a specific time-frame cannot be drawn.

Furthermore, we included articles that report on study populations recruited from the same hospitals within a recruitment time from 2004 to 2010 \[[@CR33]--[@CR37]\]. All patients were treated by chemotherapy. We did not exclude one of these studies, since 2 publications focused on a specific type \[[@CR33], [@CR37]\] and the other 3 publications included various types of cancer \[[@CR34]--[@CR36]\] with 1 study focusing on patients with different types of non-Hodgkin Lymphoma \[[@CR34]\] and 1 study with a shorter recruitment period \[[@CR35]\]. Although reported results differed, this overlap should be kept in mind.

Strengths {#Sec22}
---------

Main strength of this systematic review is its strict methodology which followed the PRISMA guideline \[[@CR31]\]. We conducted an extensive literature search without any language restrictions and did not specify search terms for outcomes to integrate all health and treatment outcomes that were investigated in primary studies. Each review step (screening, data extraction and RoB assessment) was piloted and performed by 2 reviewers independently. Additionally, we focused on 1 screening tool to minimize heterogeneity due to assessment. As part of the assessment of RoB, our rating of the confounding domain was strict and other reviewers might rate differently -- but this is a general problem with RoB rating.

Limitations {#Sec23}
-----------

The databases we used have their major focus on journals from the US and Europe and journals from other regions might not have been identified by our exhaustive systematic literature search. Therefore, language bias cannot be excluded although we did not restrict our search to specific languages.

The large heterogeneity of included studies regarding samples, treatments and outcome assessments should also be considered when interpreting our results. However, despite this heterogeneity, a rather stable relation between MNA result and several outcomes was observed.

Implications for research {#Sec24}
-------------------------

Large, prospective and registered cohort studies should be conducted to strengthen our results, which are based on heterogeneous samples and outcomes. In addition, future studies that investigate the comparison of the prognostic ability of different nutritional screening/ assessment tools (such as the MNA, the Patient-Generated Subjective Global Assessment or the Nutritional Risk Screening 2002) or criteria (such as the GLIM-criteria) are needed. Publications should follow the respective guidelines provided by the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) network (<https://www.equator-network.org/reporting-guidelines/>) to further standardize reporting of studies.

Implications for practice {#Sec25}
-------------------------

Based on our observation of negative health and treatment outcomes in patients with poor MNA-result and in light of available effective nutritional interventions, health care professionals should be aware of nutritional status and should support and engage patients to improve their nutritional status before and during anti-cancer therapy.

Conclusions {#Sec26}
===========

According to available studies, MNA-result predicts risk of mortality/survival, progression-free survival/time to progression, treatment maintenance and (health-related) quality of life in patients with cancer and does not predict adverse treatment outcomes and functional status/ decline. For other outcomes the results are less clear. A high risk of bias should however be considered. To verify these findings, further studies with good control of potential biases are needed.

Supplementary information
=========================

 {#Sec28}

**Additional file 1:Table S1.** Search strategy Medline (via Ovid). Table S3a: Results on mortality and poor overall survival (OS) (*N* = 33). Table S3b: Results on disease progression (progression-free survival (PFS) and time to progression (TTP)) (*N* = 5). Table S3c: Results on treatment maintenance or duration (*N* = 11). Table S3d: Results on adverse treatment outcomes (*N* = 15). Table 3e: Results functional status/ - decline (*N* = 4). Table S3f: Results (health-related) quality of life (*n* = 3).
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